Rocket Pharmaceuticals
RCKT
173 hedge funds and large institutions have $315M invested in Rocket Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 62 reducing their positions, and 50 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
98% more call options, than puts
Call options by funds: $2.87M | Put options by funds: $1.45M
35% more capital invested
Capital invested by funds: $233M → $315M (+$81.8M)
0.53% more ownership
Funds ownership: 88.98% → 89.52% (+0.53%)
2% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 62
12% less funds holding
Funds holding: 196 → 173 (-23)
44% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 50
Top Buyers
| 1 |
MAM
Monaco Asset Management
Monaco
|
+$7.68M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.77M |
| 3 |
Millennium Management
New York
|
+$3.85M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.77M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.72M |
Top Sellers
RCKT Hedge Fund Activity: Q3 2025 in Review
173 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2025, worth a combined $315M — up 35% from $233M a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of RCKT and 28 opened new positions — a net loss of 22 holders — while 62 trimmed existing stakes and 61 added.
The largest buyer was Monaco Asset Management, adding an estimated $7.68M. The largest seller was Toronto Dominion Bank, exiting entirely with an estimated $2.69M sold.
- 173 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2025, down from 196 in Q2 2025.
- Funds reported $315M of Rocket Pharmaceuticals stock for Q3 2025, up 35% quarter-over-quarter.
- 28 funds opened new Rocket Pharmaceuticals positions in Q3 2025 and 50 closed out, a net change of -22 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2025 was Monaco Asset Management, an estimated $7.68M added.
- The largest Rocket Pharmaceuticals seller in Q3 2025 was Toronto Dominion Bank, an estimated $2.69M sold.
Based on aggregated 13F filings for Q3 2025.